NCT07140939Not yet recruitingPhase 3
A Phase 3, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat.
Caliway Biopharmaceuticals Co., Ltd.13 sites in 2 countries300 target enrollmentStarted: September 1, 2025Last updated:
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Enrollment
- 300
- Locations
- 13
- Primary Endpoint
- Percentage of participants with at least 13% abdominal fat change and at least a 2-grade improvement on Patient Reported Abdominal Fat Rating Scale (PR-AFRS) in the CBL-514 group versus the placebo group.
Study Overview
Brief Summary
A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of CBL-514 injection for reducing abdominal subcutaneous fat.
Detailed Description
A total of approximately 300 adult participants with moderate or severe abdominal fat at Baseline 1 will be enrolled. Each participant will receive up to 4 treatments of allocated study drug administered subcutaneously to the abdomen, once every 3 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female, aged ≥ 18 years old.
- •Body mass index (BMI) > 18.5 and < 30 kg/m2 and body weight ≥ 50 kg.
- •Participant has moderate or severe abdominal fat as assessed by the Investigator on the CR-AFRS and by the participant on the PR-AFRS.
- •Participant maintained a stable lifestyle.
- •Voluntarily signs the Informed Consent Form and is physically and mentally capable of participating in the study, and willing to adhere to study procedures.
- •Exclusion Criteria
- •Female participant of childbearing potential who is not willing to commit to an acceptable contraceptive method, or who is currently pregnant or lactating. Male participant who is not committing to using condom consistently and refraining from sperm donation.
- •Participant who has impeded coagulation or platelet aggregation.
- •Participant has delayed wound healing or poorly controlled diabetes.
- •Participant has active malignancies or is currently being evaluated for a possible malignancy.
- •Participant has a history of trypanophobia, the extreme fear of medical procedures involving injections or needles, or who experiences vasovagal syncope and faints at the sight of blood or a needle.
- •Participant has a visible Panniculus on the abdomen in standing position.
- •Participant has severe abdominal visceral fat.
- •Participant has skin conditions, which would pose risk to the participant if receiving the IP or interfere with the safety or efficacy evaluation.
- •Participant has undergone the procedures at the treatment area that may affect IP administration.
- •Participant with contraindications to MRI imaging.
- •Participant is on prescription or over-the-counter weight reduction medication, weight reduction programs, or taking oral or injectable GLP-1 agonists.
- •Participant is undergoing long-term systemic steroid or immunosuppressive therapy which may affect the treatment area.
- •Participant is taking or will take any medication that is known strong inhibitor or inducer of CYP1A2 enzymes, sensitive CYP1A2 substrates, or medication with narrow therapeutic index.
- •Participant with history of hypersensitivity to local anesthesia.
- •Participant with known allergies or significant adverse reaction to the IP.
- •Participant with liver cirrhosis or abnormal liver function, or with any hepatic condition that interferes with the safety or efficacy assessments.
- •Participant with any renal impairment.
- •Participant has received any investigational product.
- •Participant considered to be unreliable or incapable of complying with the requirements of the protocol.
Exclusion Criteria
- Not provided
Arms & Interventions
CBL-514 injection
Experimental
Participants will receive CBL-514 administrated up to 120 mL (with 50 injections) per treatment at a 3-weeks interval for up to 4 treatments.
Intervention: CBL-514 Injection (Drug)
Injectable 0.9% Sodium Chloride solution
Placebo Comparator
Participants will receive 0.9% Sodium Chloride administrated up to 120 mL (with 50 injections) per treatment at a 3-week interval for up to 4 treatments.
Intervention: 0.9% Sodium Chloride (Other)
Outcomes
Primary Outcomes
Percentage of participants with at least 13% abdominal fat change and at least a 2-grade improvement on Patient Reported Abdominal Fat Rating Scale (PR-AFRS) in the CBL-514 group versus the placebo group.
Time Frame: From baseline to 4 weeks after final treatment
Measured by MRI and a 5-point ordinal scale
Secondary Outcomes
- Percentage change from baseline in abdominal fat in the CBL-514 group versus the placebo group.(From baseline to 4 weeks after final treatment)
- Percentage of participants with at least a 1-grade improvement on both Participant Reported Abdominal Fat Rating Scale (PR-AFRS) and Clinician Reported Abdominal Fat Rating Scale (CR-AFRS) in the CBL-514 group versus the placebo group.(From baseline to 4 weeks after final treatment)
Investigators
Study Sites (13)
Loading locations...
Similar Trials
Completed
Phase 3
Study of AA4500 in the Treatment of Peyronie's DiseasePeyronie's DiseaseNCT01221623Endo Pharmaceuticals418
Completed
Phase 3
Study of AA4500 in the Treatment of Peyronie's DiseasePeyronie's DiseaseNCT01221597Endo Pharmaceuticals418
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) And FibrosisCTRI/2023/11/060385Akero Therapeutics, Inc.1,000
Recruiting
Phase 3
A clinical experimental study to check the effectiveness of Selonsertib in patients with Liver Diseases due to Nonalcoholic Steatohepatitis (NASH)CTRI/2017/09/009742Gilead Sciences Inc800
Recruiting
Phase 3
A clinical experimental study to check the effect and benefits of Selonsertib in patients with Non alcoholic hepatitis (NASH) and Bridging (F3) FibrosisCTRI/2017/08/009304Gilead Sciences Inc800